Should antiplatelet medication be discontinued prior to pterygium excision and cataract extraction?

Should Antiplatelet Therapy Be Withheld Prior to Pterygium and Cataract Surgery?

No, antiplatelet therapy should NOT be routinely discontinued prior to pterygium excision or cataract surgery. These are low-risk ophthalmic procedures where the risk of thromboembolic complications from stopping antiplatelet agents far outweighs the minimal bleeding risk associated with continuing them.

Key Recommendations by Antiplatelet Agent

Aspirin (ASA)

• Continue aspirin through the perioperative period 1, 2
• Multiple studies demonstrate that aspirin continuation during cataract surgery does not increase clinically significant bleeding complications 3, 4, 5
• The 2022 CHEST guidelines support continuation of aspirin for most non-cardiac surgeries, with interruption only considered for high-bleeding-risk procedures (e.g., intracranial, spinal surgery) 6
• Cataract and pterygium surgeries do NOT fall into the high-bleeding-risk category

P2Y12 Inhibitors (Clopidogrel, Ticagrelor, Prasugrel)

The decision depends critically on coronary stent status:

If Patient Has Coronary Stents:

• Within 3 months of bare-metal stent placement: Continue BOTH aspirin AND P2Y12 inhibitor 7
• Within 12 months of drug-eluting stent placement: Continue BOTH aspirin AND P2Y12 inhibitor 1, 7
• Beyond these timeframes: May discontinue P2Y12 inhibitor while continuing aspirin 6
  • Stop clopidogrel 5 days before surgery 6
  • Stop ticagrelor 3-5 days before surgery 6
  • Stop prasugrel 7 days before surgery 6

If No Coronary Stents:

• For secondary stroke prevention: Continue aspirin 7
• For other indications without high thrombotic risk: May consider stopping P2Y12 inhibitor 5-7 days preoperatively while continuing aspirin

Evidence-Based Rationale

Why Continuation is Safe for Ophthalmic Surgery:

Cataract Surgery:

• A large prospective cohort study of 19,283 cataract surgeries found that continuing aspirin or warfarin resulted in minimal absolute differences in bleeding risk 3
• The rate of stroke/TIA/DVT was only 3.8/1000 surgeries in patients continuing anticoagulation, with no increase in vision-threatening hemorrhagic complications 3
• Studies specifically examining aspirin continuation during cataract surgery found no significant intraoperative bleeding differences 4
• When using modern phacoemulsification techniques with topical or intracameral anesthesia (avoiding needle-based blocks), bleeding risk is exceptionally low 8, 4

Pterygium Surgery:

• While specific data on antiplatelet use during pterygium surgery is limited, the procedure carries similar low bleeding risk to cataract surgery
• Combined pterygium-cataract procedures have been performed safely with good outcomes 9, 10

Critical Pitfalls to Avoid:

1. DO NOT stop dual antiplatelet therapy in patients with recent coronary stents - This carries a catastrophic risk of stent thrombosis with 50% mortality 1

2. Avoid needle-based anesthesia (retrobulbar/peribulbar blocks) in patients on antiplatelet therapy - Use topical or intracameral anesthesia instead to minimize hemorrhage risk 8, 4

3. DO NOT assume all antiplatelet users need discontinuation - The thrombotic risk of stopping often exceeds the bleeding risk of continuing for these low-risk procedures

4. Prefer clear corneal phacoemulsification over larger incision techniques in antiplatelet users 4, 11

Practical Algorithm:

Step 1: Identify indication for antiplatelet therapy

• Coronary stent? → Check timing and type
• Stroke prevention? → Continue aspirin
• Primary prevention only? → May consider stopping after risk-benefit discussion

Step 2: If coronary stent present:

• <3 months (bare-metal) or <12 months (drug-eluting)? → Delay elective surgery OR continue dual antiplatelet therapy

• 3 months (bare-metal) or >12 months (drug-eluting)? → May stop P2Y12 inhibitor, continue aspirin

Step 3: Surgical technique modifications:

• Use topical/intracameral anesthesia (NOT needle blocks)
• Employ clear corneal phacoemulsification approach
• Have cautery readily available

Step 4: Resume interrupted antiplatelet agents within 24 hours postoperatively 6

Special Considerations:

• Warfarin users: Can safely continue if INR is in therapeutic range (<3.0) 8, 3, 11
• Patients without specific medical indications: May discontinue aspirin electively 7
• Multidisciplinary consultation: Obtain cardiology input for complex cases, especially recent stent patients requiring urgent surgery 7

The evidence overwhelmingly supports that the minimal bleeding risk of continuing antiplatelet therapy during cataract and pterygium surgery is vastly outweighed by the potentially catastrophic thrombotic complications of inappropriate discontinuation, particularly in patients with coronary stents or cerebrovascular disease.